Malignant Digestive System Neoplasm

Rogaratinib (BAY 1163877) treatment was tested in vivo in a cell line-derived model of NCI‐H716 human colon cancer. This model has FGFR2 amplifications and highly elevated FGFR2 mRNA. Mice were trea… (full text at CIViC)

PMID 30807645 · Grünewald et al., 2019 · Open in CIViC

In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC)

PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC

In a 43 year old female patient with this fusion in intrahepatic cholangiocarcinoma. Both pazopanib and ponatinib separately resulted in minor tumor shrinkage. This fusion is also shown to be recurren… (full text at CIViC)

PMID 24550739 · Borad et al., 2014 · Open in CIViC

In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC)

PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC

In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC)

PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC

ARQ 087 exhibited inhibitory effects biochemically, in cell line and cell cycle study of FGFR2 functions.

PMID 27627808 · Hall et al., 2016 · Open in CIViC

The authors detail a phase 1 dose-expansion trial of a pan-FGFR inhibitor, fubatinib. Most FGFR inhibitors are reversible ATP-competitor inhibitors that tumors can acquire resistance to. Futibatinib, … (full text at CIViC)

PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC

Actionable fibroblast growth factor receptor 2 (FGFR2) fusions have been identified in intrahepatic cholangiocarcinomas (iCCA). Derazantinib, a multi-kinase inhibitor with potent pan-FGFR activity sho… (full text at CIViC)

PMID 30420614 · Mazzaferro et al., 2019 · Open in CIViC

In the phase 2 trial (NCT02052778), 103 patients (22-79 years of age) with unresectable or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements were treated with the … (full text at CIViC)

PMID 36652354 · Goyal et al., 2023 · Open in CIViC

In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC)

PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC

In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC)

PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC

The phase II NCI-MATCH trial (EAY131) subprotocol W assessed the FGFR1-3 selective TKI AZD-4547 in 48 patients with FGFR1/2 amplifications, FGFR2/3 SNV or FGFR1/3 fusions. The partial response overall… (full text at CIViC)

PMID 32463741 · Chae et al., 2020 · Open in CIViC

In a panel of 14 cell lines representing multiple tumor types (endometrial, bladder, gastric, breast, lung, and colon) and containing FGFRs dysregulated by a variety of mechanisms, ponatinib inhibited… (full text at CIViC)

PMID 22238366 · Gozgit et al., 2012 · Open in CIViC

The study analysed the expression of the two splice variants of FGFR3 (FGFR3-IIIb and FGFR3-IIIc/FGFR3-IIIc-KD) in two pancreatic ductal adenocarcinoma cell lines (Capan-2 and BxPC-3). The FGFR3-IIIc-… (full text at CIViC)

PMID 23902722 · Lafitte et al., 2013 · Open in CIViC

In this report, Mizukami et al. explored major FGFR1, FGFR2, and FGFR3 fusion transcripts in ESCC and GC specimens (n = 74 and 114, respectively) using a most comprehensive next-generation sequencing … (full text at CIViC)

PMID 27771611 · Mizukami et al., 2017 · Open in CIViC

In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC)

PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC

Identification of an oncogenic mutation in FGFR4 in a human gastric tumour that leads to constitutive activation and sensitivity to ASP5878.

PMID 31601997 · Futami et al., 2019 · Open in CIViC

Among 45 patients with recurrent hepatocellular carcinoma treated with sorafenib, one patient whose tumor harbored FGFR4 G665E achieved a partial response. The same tumor also harbored FGFR2 M538I, pr… (full text at CIViC)

PMID 27384874 · Kaibori et al., 2016 · Open in CIViC

A patient with metastatic colon cancer who was previously treated with more than 3rd line cytotoxic chemotherapy was found to have FLT3 amplification and then received regorafenib showing partial resp… (full text at CIViC)

PMID 27906677 · Lim et al., 2017 · Open in CIViC

Treatment with sorafenib of a patient with metastatic colorectal cancer and FLT3 translocation who had previously been heavily treated showed significant symptomatic and laboratory improvement with so… (full text at CIViC)

PMID 25848357 · Moreira et al., 2015 · Open in CIViC

A 67-year-old female presents with recurrent metastatic colonic adenocarcinoma. Immunohistochemical and genetic workup showed overexpression of c-JUN and FOS, which presumably signals through the RAA… (full text at CIViC)

PMID 27022066 · Jones et al., 2016 · Open in CIViC

Continuous exposure to oxaliplatin was used to produce an oxaliplatin resistant HCT116 cell line (HCT116/OXA), that showed significantly higher IC50 (145.5 ± 3.52 μM vs. 7.53 ± 0.63 μM) than the paren… (full text at CIViC)

PMID 32110058 · Chen et al., 2020 · Open in CIViC

As high expression of FOXF1 was associated with higher progression, poorer survival, and increased microvessel density in colorectal cancer (CRC) patients (p < 0.001), the in vitro effects of bevacizu… (full text at CIViC)

PMID 30253191 · Wang et al., 2018 · Open in CIViC

shRNA-mediated reduction of FPGS expression increased fluorouracil sensitivity in colorectal cancer cells, producing approximately threefold and sixfold decreases in IC50 in HCT-116 and HT-29 cells, r… (full text at CIViC)

PMID 21449674 · Muhale et al., 2011 · Open in CIViC

From October 2015 to April 2019, 103 HCC patients scheduled to receive chemoembolization were screened. Of them, 84 met inclusion criteria and were assigned to TT (TACE) (n = 25), Non-TT (TACE) (n = 3… (full text at CIViC)

PMID 34982369 · Chen et al., 2022 · Open in CIViC

Reduced GGH expression by shRNA significantly sensitized HCT-116, HT-29, and SW620 colorectal cancer cells to fluorouracil. Across the DHFR/GGH experiments (note that these are summarized together in-… (full text at CIViC)

PMID 21449674 · Muhale et al., 2011 · Open in CIViC

In a retrospective study of 151 patients with sporadic colorectal cancer, 5-year survival rate was significantly higher in patients with International Union Against Cancer (UICC) stages I to II (mean … (full text at CIViC)

PMID 16033819 · Frey et al., 2005 · Open in CIViC

Intrahepatic cholangiocarcinomas of patients with homozygous TT genotypes revealed a higher proliferation rate and a lower apoptotic rate.This study demonstrated a significant association of both dise… (full text at CIViC)

PMID 17356712 · Schmitz et al., 2007 · Open in CIViC

In ex vivo human tumor slice models of mucinous cancers, GNAS-mutant tumors showed greater sensitivity to palbociclib than GNAS wild-type (WT) tumors, with significantly reduced proliferation followin… (full text at CIViC)

PMID 39413348 · Weitz et al., 2025 · Open in CIViC

Case of a patient with appendiceal adenocarcinoma with mucinous peritoneal carcinomatosis who was treated with trametinib upon identification of a GNAS R201H mutation and had clinical benefit for 4 mo… (full text at CIViC)

PMID 28868010 · Ang et al., 2017 · Open in CIViC

This case study reports a 78 year old patient with pancreatic adenocarcinoma harboring a GP2::NTRK1 gene fusion characterized by an in-frame rearrangement involving exon 2 of GP2 and exon 8 of NTRK1. … (full text at CIViC)

PMID 42412359 · Tazuma et al., 2026 · Open in CIViC

Patients with the GSTP1 I105V variant had greater response to FOLFOX-4 treatment, longer progression-free survival, and longer overall survival. 166 Chinese patients with metastatic colorectal carcino… (full text at CIViC)

PMID 19922504 · Chen et al., 2010 · Open in CIViC

HDAC expression was assessed from 27 esophageal squamous cell carcinoma (ESCC) cell lines to determine the efficacy of HDAC inhibitors and found that practically all 10 HDAC (HDAC1, HDAC2, HDAC3, HDAC… (full text at CIViC)

PMID 30484863 · Cheng et al., 2018 · Open in CIViC

In 62 esophageal carcinoma tumor samples, HDAC1 expression was found to considerably increase by 82% compared to adjacent non-tumor tissues with (18.2%) and identified as HDAC1 positive. HDAC1 positiv… (full text at CIViC)

PMID 31908417 · Zhu et al., 2019 · Open in CIViC

The HIF1A rs2057482 SNP was genotyped in 410 pancreatic ductal adenocarcinoma cases and 490 healthy controls. The CC genotype was significantly correlated with PDAC risk (OR = 1.719, 95% CI: 1.293-2.2… (full text at CIViC)

PMID 26872370 · Wang et al., 2016 · Open in CIViC

HIF1A overexpression was assessed by IHC in 731 colorectal cancers from two prospective cohort studies. 142 (19%) tumors showed HIF1A overexpression. Overexpression of HIF1A was associated with higher… (full text at CIViC)

PMID 20363910 · Baba et al., 2010 · Open in CIViC

A patient with metastatic colorectal cancer was enrolled in a phase 2 clinical trial (NCT01174121). 24 cultures of tumor-infiltrating lymphocytes were expanded from 3 lung metastasis resections. After… (full text at CIViC)

PMID 27959684 · Tran et al., 2016 · Open in CIViC

In an in vitro study, DiFi colorectal cancer cell lines stably expressing HRAS G12V mutation demonstrated resistance to cetuximab treatment compared to DiFi cells expressing wild-type HRAS. Resistance… (full text at CIViC)

PMID 22797062 · Kasper et al., 2013 · Open in CIViC

In an in vitro study, Colo-320, SW48, and CaCO2 cell lines expressing HRAS G13D mutation were associated with resistance to cetuximab treatment, as compared to Colo-320, SW48, and CaCO2 cells expressi… (full text at CIViC)

PMID 26561417 · Boidot et al., 2016 · Open in CIViC

Case report of a patient with metastatic colorectal carcinoma and a novel HRAS G13D mutation showed resistance to treatment with panitumumab. In vitro models of HRAS G13D confirmed resistance mechanis… (full text at CIViC)

PMID 26561417 · Boidot et al., 2016 · Open in CIViC

Expression of GRP78 (HSPA5) in colorectal cancer patients (n=396, by IHC) showed improved benefit from adjuvant chemotherapy in stage III patients (52% vs. 28%; p = 0.026). In vitro, GRP78 inhibition … (full text at CIViC)

PMID 23456958 · Thornton et al., 2013 · Open in CIViC